Table 1.
Demographic and baseline characteristics
| EEG +LPD/ES (N=17) | EEG −LPD/ES (N=15) | p-value | |
|---|---|---|---|
| Age at diagnosis, mean (range) | 62 (41–82) | 67 (50–86) | 0.32 |
| Female sex, N(%) | 7 (41%) | 3 (20%) | 0.27 |
| KPS, median (range)a | 80 (20–100) | 80 (20–90) | 0.76 |
| Pathology integrated diagnosis, N(%)b | |||
| Glioblastoma | 13 (76%) | 15 (100%) | 0.10 |
| Diffuse glioma NEC | 4 (24%) | 0 (0%) | |
| WHO grade, N(%)b | |||
| Grade 4 | 13 (76%) | 15 (100%) | 0.10 |
| Grade 3 | 3 (18%) | 0 (0%) | |
| Grade 2 | 1 (6%) | 0 (0%) | |
| MGMT promoter methylated, N(%)c | 10 (77%) | 5 (38%) | 0.14 |
| Gross total resection, N(%) | 5 (29%) | 7 (47%) | 0.47 |
| Completed chemoradiation, N(%) | 13 (76%) | 12 (80%) | 1.00 |
| Tumor localization, N(%)d | |||
| Temporal/Insular | 9 (53%) | 10 (67%) | 0.49 |
| Frontal | 6 (35%) | 3 (20%) | |
| Parietal | 5 (29%) | 2 (13%) | |
| Occipital | 1 (6%) | 1 (7%) | |
| Thalamic | 1 (6%) | 0 (0%) | |
| Clinical seizures at presentation, N(%) | 14 (82%) | 10 (67%) | 0.42 |
| Clinical seizures at anytime, N(%) | 16 (94%) | 11 (73%) | 0.16 |
| ASMs received peri-operatively, N(%) | 17 (100%) | 15 (100%) | 1.00 |
| ASMs at start of continuous EEG, N(%) | 16 (94%) | 14 (93%) | 1.00 |
ASM, anti-seizure medication; KPS, Karnofsky Performance Status; LPD/ES, lateralized periodic discharge and/or electrographic seizure; MGMT, O[6]-methylguanine-DNA methyltransferase; WHO, World Health Organization
a
KPS determined at initial post-operative pre-treatment evaluation
b
Re-coded to align with 2021 WHO Classification criteria
c
Percent of cases with available data; −LPD/SZ (N=13), +LPD/SZ (N=13)
d
Multi-lobar cases counted in each applicable category